Systemic and regional hemodynamic effects of gallopamil in patients with essential hypertension

R G Ketelhut1, F H Messerli, C Losem

  • 1Medizinische Poliklinik, Universitäts-Klinikum Charité, Berlin, Germany.

Insights

Gallopamil effectively lowers blood pressure and vascular resistance in hypertensive patients. This essential hypertension treatment did not cause fluid retention or lasting heart rate changes.

Area of Science:

  • Cardiovascular Medicine
  • Pharmacology

Background:

  • Essential hypertension is a prevalent cardiovascular condition.
  • Managing blood pressure while avoiding adverse hemodynamic effects is crucial.

Purpose of the Study:

  • To evaluate the hemodynamic effects of gallopamil in patients with essential hypertension.
  • To assess the impact of gallopamil on systemic and regional hemodynamics.

Main Methods:

  • Hemodynamic parameters were measured in 10 hypertensive patients before and during gallopamil therapy.
  • Cardiac output was determined using indocyanine dye; plasma volume and renal blood flow were measured radioisotopically.

Main Results:

  • An initial dose of slow-release gallopamil reduced arterial pressure and total peripheral resistance, with a transient increase in heart rate and cardiac output.
  • Sustained gallopamil treatment (8-12 weeks) maintained reduced arterial pressure and peripheral resistance without altering heart rate or cardiac output.
  • Gallopamil significantly decreased renal and splanchnic vascular resistance, without affecting plasma or total blood volume.

Conclusions:

  • Gallopamil effectively reduces arterial pressure and vascular resistance in essential hypertension.
  • The antihypertensive effect of gallopamil is achieved without significant fluid retention or prolonged reflex cardiovascular stimulation.

Related Concept Videos

Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Hypertension III: Clinical Manifestations and Diagnostic Studies01:30

Hypertension III: Clinical Manifestations and Diagnostic Studies

Hypertension is asymptomatic and also referred to as the "silent killer" until it progresses to a severe stage or causes target organ disease. Patients may experience symptoms stemming from the strain on blood vessels and tissues in various organs or the heart's increased workload.Physical exams might show no abnormalities other than high blood pressure. Signs of vascular damage, when present, correspond to the organs supplied by the affected vessels, leading to target organ damage. For...